14 September 2023
Maxwellia launches new brand of emergency contraception
In their latest move to help widen access to medicines, Maxwellia is delighted to announce the launch of LoviOne®; a new brand of levonorgestrel-based emergency contraception. Set to hit pharmacy shelves this autumn, LoviOne® aims to improve access to emergency contraception...
4 September 2023
Gendius receives UKCA mark for CKD Screen Prioritizer
British health data start-up Gendius has received a UKCA mark for its digital pre-screening technology, the CKD Screening Prioritizer (CSP). The CSP, which is now a registered medical device in the UK, uses readily available data to predict whether a patient is likely to be...
22 August 2023
Infex receives approval for dosing final RESP-X Phase Ia cohort and first-in-patient Phase IIa
Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives specialist, announces it has received approval to commence dosing the final Phase Ia cohort of healthy volunteers and to proceed to dosing the first cohort in the first-in-patient Phase IIa dose-ranging...
16 August 2023
Infex Therapeutics - Clinical candidate nominated for COV-X programme
COV-X is a novel first-in-class small molecule oral pan-coronavirus antiviral candidate … • COV-X outperforms Pfizer’s approved antiviral in a pre-clinical mouse SARS-CoV-2 efficacy trial … • Unlike many competitors, COV-X blocks a unique key protein and has potential for broad...
5 July 2023
Oxford BioTherapeutics initiates Phase Ib clinical trial for OBT076 in patients with advanced solid tumours
… • OBT initiates clinical combination study for both CPI-naïve and resistant patients with advanced solid tumours by dosing first patient with OBT076 in combination with checkpoint inhibitor (CPI) balstilimab. • The Phase Ib combination study for OBT076 builds on previous...
29 June 2023
CPI Enterprises to help fund innovative medical device for brain tumours
CPI Enterprises have invested in a medical device which could dramatically increase long-term survival for people with the most common and aggressive type of brain tumours. This is CPI Enterprises’ ninth investment and fourth in the last 12 months. … QV Bioelectronics, based at...
15 June 2023
AI influencer tackles TikTok health trend
Alderley Park, Cheshire, UK – 10th June 2023 Contraceptive pill brand, Lovima® has created an AI influencer to help educate young women about hormonal contraception in response to the latest TikTok health trend. #gettingoffbirthcontrol has over nine million views on TikTok, and...
5 June 2023
Cytox brings ground-breaking genetic risk test for Alzheimer's disease to the UK
1st June 2023 - There are currently around 900,000 people in the UK living with dementia, and this number is expected to rise to over 1 million by 2025. Alzheimer's disease (AD) is the most common type of dementia in the UK, accounting for around two-thirds of all cases. Today...
25 May 2023
Oxford BioTherapeutics and Boehringer Ingelheim agree on extension to second multi-year collaboration in cancer immunology
Oxford, UK and San Jose, Calif., 25 May 2023 – Oxford BioTherapeutics Ltd. (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and antibody-drug conjugate (ADC)-based therapies, today announced that it has extended its second multi-year collaboration with...
16 May 2023
Study by Healum demonstrates its platform improves health outcomes for diabetes patients
A randomised control study to explore the impact and efficacy of the Healum Collaborative Care planning Software and App on condition management for Type 2 diabetes (T2D) patients in NHS primary care has produced promising results that have been shown to improve health outcomes.